Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDM-guided piperacillin dosing in severe sepsis or septic shock
2016-000136-17Phase 3Completed
- Sponsor
- Friedrich Schiller University Jena
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of piperacillin in sepsis, septic shock and bacterial disease (2 arms), sponsored by Friedrich Schiller University Jena. Primary endpoint: Mean total SOFA score. Started Apr 2016; status: completed.
02
Drugs
03
Conditions
sepsisseptic shockbacterial disease
Beyond the preview
Go deeper on 2016-000136-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000136-17.